**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 88543

**Manuscript Type:** MINIREVIEWS

**The role of computed tomography for the prediction of esophageal variceal bleeding: Current status and future perspectives**

Martino A *et al*. Role of CT for EVB prediction

Alberto Martino, Lucio Amitrano, Marianna Guardascione, Marco Di Serafino, Raffaele Bennato, Rossana Martino, Annalisa de Leone, Luigi Orsini, Luigia Romano, Giovanni Lombardi

**Alberto Martino, Lucio Amitrano, Marianna Guardascione, Raffaele Bennato, Rossana Martino, Annalisa de Leone, Luigi Orsini, Giovanni Lombardi,** Department of Gastroenterology and Digestive Endoscopy, AORN “Antonio Cardarelli”, Napoli 80131, Italy

**Marco Di Serafino, Luigia Romano,** Department of General and Emergency Radiology, AORN “Antonio Cardarelli”, Napoli 80131, Italy

**Author contributions:** Martino A, Amitrano L, Guardascione M and Di Serafino M designed research and wrote, edited and finalized the text; Martino A, Amitrano L, Guardascione M, Di Serafino M, Bennato R, Martino R and de Leone A performed literature search and analyzed the data; Orsini L, Romano L and Lombardi G reviewed the paper for important intellectual content.

**Corresponding author: Alberto Martino, MD, Staff Physician,** Department of Gastroenterology and Digestive Endoscopy, AORN “Antonio Cardarelli”, Via Antonio Cardarelli, 9, Napoli 80131, Italy. alberto.martino@aocardarelli.it

**Received:** September 27, 2023

**Revised:** November 13, 2023

**Accepted:** November 27, 2023

**Published online:** December 16, 2023

**Abstract**

Esophageal variceal bleeding (EVB) is one of the most common and severe complications related to portal hypertension (PH). Despite marked advances in its management during the last three decades, EVB is still associated with significant morbidity and mortality. The risk of first EVB is related to the severity of both PH and liver disease, and to the size and endoscopic appearance of esophageal varices. Indeed, hepatic venous pressure gradient (HVPG) and esophagogastroduodenoscopy (EGD) are currently recognized as the “gold standard” and the diagnostic reference standard for the prediction of EVB, respectively. However, HVPG is an invasive, expensive, and technically complex procedure, not widely available in clinical practice, whereas EGD is mainly limited by its invasive nature. In this scenario, computed tomography (CT) has been recently proposed as a promising modality for the non-invasive prediction of EVB. Although CT is only a diagnostic modality, thus being not capable of supplanting EGD or HVPG in providing therapeutic and physiological data, it could potentially assist liver disease scores, HVPG, and EGD in a more effective prediction of EVB. However, to date, evidence concerning the role of CT in this setting is still lacking. Our review aimed to summarize and discuss the current evidence concerning the role of CT in predicting the risk of EVB.

**Key Words:** Esophageal variceal bleeding; Variceal upper gastrointestinal bleeding; Portal hypertension; Computed tomography; Computed tomography angiography

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Martino A, Amitrano L, Guardascione M, Di Serafino M, Bennato R, Martino R, de Leone A, Orsini L, Romano L, Lombardi G. The role of computed tomography for the prediction of esophageal variceal bleeding: Current status and future perspectives. *World J Gastrointest Endosc* 2023; 15(12): 681-689

**URL:** <https://www.wjgnet.com/1948-5190/full/v15/i12/681.htm>

**DOI:** https://dx.doi.org/10.4253/wjge.v15.i12.681

**Core Tip:** Esophagogastroduodenoscopy is currently considered the diagnostic reference standard for the prediction of esophageal variceal bleeding (EVB) among cirrhotic patients. Recently, computed tomography (CT) has emerged as a promising tool for the non-invasive prediction of EVB. Nevertheless, to date, evidence concerning the role of CT in this setting is still lacking. Thus, our study aimed to review the current evidence regarding the role of CT in the prediction of EVB.

**INTRODUCTION**

Variceal upper gastrointestinal bleeding (VUGIB) is one of the most severe and common complications related to portal hypertension (PH) occurring in patients affected by liver cirrhosis. The annual incidence of esophageal varices (EV) among cirrhotic patients is 7%-8%, with a five-year cumulative incidence rate reaching approximately 20%. Furthermore, once EV develop, their risk of first bleeding is 5%-15% per year, being related to the severity of both PH and liver disease, and to the size and endoscopic appearance of EV[1-3].

Despite marked advances in its management during the last three decades, VUGIB is still a potentially life-threating event with a high morbidity and a 6-week mortality as high as 10%-20%[4,5]. Moreover, esophageal variceal bleeding (EVB) is a negative prognostic factor. Indeed, the mortality of patients sustaining a EVB is as high as 35% at 3 mo and 70% at 2 years[6,7]. Thus, it is of paramount importance to carefully identify cirrhotic patients with a high-risk of EVB requiring prompt primary prophylaxis, in order to reduce first EVB incidence and improve the overall survival[8].

Nowadays, screening for EV by means of esophagogastroduodenoscopy (EGD) is suggested in decompensated cirrhotic patients, whereas primary prophylaxis is recommended in patients with cirrhosis and medium-large size varices and in those with small size varices as long as they are classified as Child-Pugh C or have variceal red signs[9-13]. Currently recommended strategies for the EVB primary prophylaxis include the use of traditional non-selective beta-blockers (NSBB), carvedilol or endoscopic variceal ligation (EVL)[9-13]. However, the superiority of one prophylactic alternative over the others is controversial. Indeed, while EVL might be superior to pharmacological therapy regarding the prevention of the first bleeding episode, either traditional NSBB or carvedilol seem to play a more crucial role in the mortality reduction. Furthermore, although not routinely recommended as a first-line option, combined pharmacological and endoscopic primary prophylaxis has been reported to be capable to achieve a greater reduction in the risk of the first EVB episode[14]. EGD is currently regarded as the diagnostic reference standard for detecting the presence of EV and predicting their bleeding risk[9-13]. The North Italian Endoscopy Club index and its variations, composed of scores for Child-Pugh class, EV size, and red wale markings, are validated as significant predictors of first EVB[3,15,16].

However, EGD is invasive and capable to identify EV within only the superficial portions of intrinsic veins, ignoring the remaining esophageal venous plexuses[17]. Furthermore, only about a third of EVB patients have risk factors predictive of hemorrhage, such as large EV size, endoscopic red color signs, and severe liver dysfunction[3]. Finally, of note, inter-observer EV size agreement has been reported to be higher by the use of CT as compared to endoscopy[18,19].

In addition to EGD, hepatic venous pressure gradient (HVPG) is recognized as the “gold standard” for the measurement of portal pressure, the prediction of the occurrence of EVB and other PH-related complications, and for the assessment of the response to pharmacological treatment[9,10,20]. Clinically significant PH, which is an at-risk condition for decompensation and EV development, is defined by HVPG ≥ 10 mmHg, whereas a gradient > 12 mmHg defines severe PH, which is associated with a higher risk of EVB and mortality[11,21]. Indeed, an HVPG threshold value > 12 mmHg was shown to be necessary for the occurrence of EVB[22,23]. Furthermore, a decrease of baseline HVPG to ≤ 12 mmHg or by ≥ 20% by beta-blockers has been shown to be associated with a significant reduction in the risk of EVB and mortality[24].

However, HVPG is an invasive and expensive procedure, requiring high expertise. Thus, it is not readily and widely available in clinical practice, and its cost-effectiveness has been also questioned[25]. Moreover, the clinical utility of repeated monitoring HVPG after pharmacological therapy has not been established[26].

In this scenario, a promising role of computed tomography (CT) in the non-invasive prediction of EVB has been suggested. CT is commonly performed in cirrhotic patients, as in the case of hepatocellular carcinoma screening/follow-up or first decompensation episode investigation. To date, CT angiography has shown good accuracy in the detection and grading of EV[27]. However, only a few studies have explored the utility of information provided by CT imaging to predict EVB, and evidence is still limited. Although CT is only a diagnostic modality, thus being not capable of supplanting EGD or HVPG in providing therapeutic and physiological data, it could potentially assist liver disease scores, HVPG, and EGD in a more effective prediction of EVB.

The aim of our study was to extensively review the current evidence with regard to the role of CT in the prediction of EVB among cirrhotic patients.

**LITERATURE SEARCH**

We performed a comprehensive literature search of the PubMed (MEDLINE) and EMBASE electronic databases up to June 2023, in order to identify relevant studies evaluating the role of CT in the prediction of EVB among cirrhotic patients. Studies evaluating the VE presence only or comparing CT findings with endoscopic grade of EV were not included in our review. The medical search strategy used the terms "computed tomography", "CT", "computed tomography angiography", "CTA", “multidetector computed tomography”, "MDCT", "variceal upper gastrointestinal bleeding", "variceal upper gastrointestinal haemorrhage", “esophageal variceal haemorrhage” and “esophageal variceal bleeding” in various combinations, using the Boolean operators AND, OR, and NOT. Search strategy was limited to non-animal studies conducted in adult population, and to articles written in English. Meeting abstracts, case reports/series (< 10 cases), review articles, position papers, editorials, commentaries, and book chapters were excluded from our study.

The reference lists of pertinent identified studies and related review articles were carefully hand-searched in order to retrieve any additional eligible studies.

**ROLE OF CT IN THE PREDICTION OF EVB**

***Evidence***

A total of 9 studies were included in our final analysis[28-36]. All of them were retrospective, single-center studies[28-36]. All but two European and one American studies, were from Asian countries. Intravenous contrast-enhanced CT, with at least one portal venous phase, was performed in all of the included studies. With the exception of one study[28], no contrast medium was orally administered in any of the included studies. Multidetector CT (MDCT) technology was adopted in most of the included studies[28,30-32,35,36]. Main characteristics of the included studies are summarized in Tables 1-3.

In 2014, Somsouk *et al*[28] first retrospectively evaluated the role of MDCT angiography in predicting the occurrence of EVB among cirrhotic patients. A large maximal EV diameter was shown to be significantly associated with EVB. Furthermore, an MDCT threshold of < 3 mm and ≥ 5 mm appeared to discriminate between low- and high-risk individuals, respectively. Other CT findings, including the size of the paraumbilical vein (PUV), the coronary vein, and the presence of ascites reached statistical significance, but less powerfully discriminated for EVB. Conversely, neither portal vein diameter nor spleen size showed significant association with EVB. Of note, the model for end-stage liver disease (MELD) score measured at the time of the CT execution was not significantly different between the bleeding and the control groups. However, among the included patients who experienced EVL, the average time between CT and EVB was 7 mo. Moreover, another limitation of the study is the inclusion of patients undergoing EVB pharmacological prophylaxis in both the bleeding and the control groups[28].

Later on, Ge *et al*[29] showed not only EV diameter but also diameter of inferior mesenteric vein (IMV), posterior gastric vein, and short gastric vein were significantly correlated with EVB among HBV cirrhotic patients. For IMV and short gastric vein, the smaller the diameters, the higher hemorrhage rates were, whereas for EV and posterior gastric vein, the EVB rate was proportional to the diameter. Of note, the authors did not measure the EV diameter only, but a previously reported radiological score was adopted, providing the following 3 grades: (1) One varix less than 5 mm in diameter detected on the inner surface of the esophagus; (2) several varices less than 5 mm in diameter detected on the inner surface of the esophagus; and (3) one varix 5 mm or greater in diameter, or varices occupying more than half the circumference of the esophagus[37]. Conversely, no significant correlation was found with portal vein, superior mesenteric vein, splenic vein, PUV, coronary vein, spleno-renal shunt, short gastric vein, and azygos vein. Notably, a significant difference in term of Child-Pugh was observed between the bleeding and the control group[29].

In 2017, Calame *et al*[30] retrospectively evaluated the association between the presence/size of PUV on CT and a first EVB in 172 cirrhotic patients. The authors showed that a small/absent PUV was significantly associated with a first EVB. Moreover, the authors observed no case of first EVB in any patients with a PUV > 10 mm, assuming that a large patent PUV may act in a transjugular intrahepatic portosystemic shunt-like manner, lowering portal venous pressure. The presence of an enlarged left gastric vein (LGV), *i.e.* when tortuous and > 3 mm, was also significantly more frequent in patients with a first EVB. Conversely, LGV diameter and presence or diameter of spleno-renal shunt were not associated with first EVB. The study findings were in contrast with those from Somsouk *et al*[28], who reported a significant positive association of PUV diameter with EVB, as well with those from other groups who did not report any significant association between PUV and EVB[29,32]. To be noted, the most common etiology of cirrhosis in both the bleeding and the control groups was alcoholic, in which the PUV prevalence is probably higher as compared with other cirrhosis etiology, likely affecting the study outcomes. Moreover, Child-Pugh score was significantly different between the two groups[30].

Later on, a well-designed retrospective study from South Korea evaluated the utility of CT-measured liver volume for the prediction of EVB during primary prophylaxis with propranolol. Of interest, liver volume index, an estimated-to-actual liver volume index corrected for patients’ body build, was shown to be significantly higher in the prophylaxis failure group, indicating that corrected liver volume was significantly smaller in patients without prophylaxis failure. Conversely, hepatic and spleen volumes were not significantly different between the case and control groups. Notably, neither Child-Pugh nor MELD scores were predictive of prophylaxis failure[31].

Subsequently, a single center retrospective study from Iran investigated the role of abdominal MDCT angiography in the prediction of EVB, comprehensively evaluating the value of different collateral veins. Intriguingly, the presence of EV on MDCT together with the presence and/or the size of various collaterals, including coronary, short gastric, paraesophageal, and paraesophageal draining, showed a significant relationship with EVB. The presence of EV on MDCT was defined as enhancing dots and linear structures within esophageal wall or protruded into the esophageal lumen[38]. In addition, size of main coronary vein, gastric fundus varices and IMV, and ascites also had significant correlation with EVB. Conversely, omental, perisplenic and spleno-renal collaterals, spleen size, PUV size/presence, size of portal vein, inferior vena cava, superior mesenteric vein and left renal vein did not show any significant association with EVB. However, of note, all of the above-mentioned CT features were also associated with EV presence, thus limiting their clinical usefulness in the prediction of EVB. Furthermore, the bleeding and non-bleeding groups significantly differed with regard to MELD score and Child-Pugh class[32].

In 2020, the largest included study from China retrospectively evaluated the accuracy of the diameter of EV, the number of cross-sectional EV, and the total cross-sectional area of EV in the prediction of first EVB among 264 cirrhotic patients. All of these 3 EV indicators were shown to be significantly associated with first EVB. Of interest, the EV total cross-sectional area showed a higher accuracy, with a sensitivity of 0.75, a specificity of 0.73, and a critical point of 1.03 cm2. The main limitation of this study was the absence of data regarding the liver function and the cirrhosis stage of the included patients[33].

Later on, Peisen *et al*[34] failed to identify any significant correlation between hepatic perfusion index, portal venous perfusion, and splenic blood flow, measured by means of perfusion CT, and EVB. However, of note, the study was limited by a very small sample size, including only a very few cases of EVB (8/66) and Child-Pugh class C patients (6/66). Indeed, the authors concluded that their results should be limited to patients in Child-Pugh class A and B.

In 2021, Wan and colleagues conducted a well-designed retrospective study in order to evaluate the role of CT-derived quantitative parameters of liver lobe volume in the prediction of first EVB. Caudate volume, caudate functional volume, caudate volume/total volume, and caudate functional volume/total functional volume were all shown to be significantly associated with first EVB. However, all these features were also associated with the EV severity. Moreover, given the rigorous inclusion criteria and the follow-up strategy, another study limitation was the small sample sizes of both the first-EVB and non-first EVB groups[35].

Finally, the same group investigated the potential of various quantitative CT-derived parameters, including EV grade, EV diameter, cross-sectional surface area, EV volume, spleen volume, splenic vein, portal vein, diameter of LGV, and the opening type of LGV, in predicting the risk of EVB. The EV grading system on CT images was made in accordance with the criteria proposed by Kim *et al*[39], classifying EV as I–IV mainly according to the EV diameter and their distribution around the inner wall. Although some of these CT parameters proved to be significantly associated with EV severity, none of them showed a significant association with EVB. However, as stated by the same authors, the enrolled study population was mainly composed of patients with severe EV, bringing a potential bias of the study cohort, and large samples with more patients with mild to moderate EV would have been warranted to reach high-quality evidence for further validation[36].

**CONCLUSION**

As expected, EV diameter/grade was the CT feature significantly associated with EVB most frequently reported among the included studies[28,29,32,33]. Conversely, with regard to major collateral vessels, LGV size/enlargement was shown to be significantly associated with EVB in only two of the included studies[28,30]. PUV showed conflicting results in the prediction of EVB in two studies[28,30]. As previously mentioned, this may be explained by an enrollment bias in the study from Calame *et al*[30], in which the alcoholic etiology of cirrhosis was prevalent. Moreover, IMV size was shown to be a significant predictor of EVB in two studies[29,32], while the size of posterior gastric vein and short gastric vein was demonstrated as such only in one study, respectively[29,32]. Finally, none of the included studies found a significant association of spleno-renal vein with EVB occurrence.

Worth mentioning, portal-systemic collaterals development varies from patient to patient, being likely influenced by the etiology of cirrhosis, and with each subject showing his own pattern, either single or a combination of multiple collaterals[40,41]. Moreover, with the exception of LGV, the value of these collaterals in the prediction of EVB has not been clearly established[41,42].

EGD is currently regarded as the diagnostic reference standard for the prediction of EVB, being capable to identify high-risk EV, such as medium or large-sized, and small-sized with red wale markings EV[9]. Furthermore, primary prophylaxis against EVB is recommended in cirrhotic patients with high-risk EV and in those with small size EV who are classified as Child-Pugh C class[9-13]. Nevertheless, the occurrence of EVB during primary prophylaxis with propranolol has been reported in up to 30% of cases[11]. HVPG is considered the “gold standard” for the assessment of the response to pharmacological prophylaxis and may be adopted in order to reduce the rate of primary prophylaxis failure[9,10,24]. However, HVPG is invasive and expensive. Moreover, it is not readily and widely available in routine clinical practice, and its cost-effectiveness and clinical usefulness have also been questioned[25,26].

EGD is invasive, costly, and potentially associated with the risk of iatrogenic bleeding. With regard to high-risk EV identification, a lower inter-observer agreement of EGD has also been reported as compared with CT imaging[18,19]. Moreover, frequent endoscopic screening may result in poor patients’ compliance and loss of patients to follow-up[22,43]. Despite these limitations, in our opinion, CT should not be intended to replace EGD in the prediction of EVB. Nevertheless, CT may be useful in the identification of patients with a very-high risk of EVB. Given that CT is increasingly performed with various indications among cirrhotic patients, it could potentially assist liver disease scores, HVPG, and EGD in a more effective prediction of EVB. Moreover, CT may be able to support clinicians in their daily practice in accurately identifying very high-risk patients for EVB, in whom a combined pharmacological and endoscopic primary prophylaxis may be systematically considered and/or a more aggressive therapeutic monitoring strategy may be adopted.

Of note, all of the included studies in our review demonstrated severe limitations, likely affecting the study outcomes. First of all, bleeding and control groups significantly differed in terms of Child-Pugh class and/or MELD score in three out of 9 studies[29,30,32], whereas liver disease scores were not reported in another study[33]. Second, their retrospective nature[28-36]. Lastly, their small sample size[28-36].

The role of CT in the prediction of EVB, especially by the measurement of various EV indicators and some collateral veins, appears to be promising and intriguing. However, to date, evidence is still lacking. In our opinion, large, multicenter prospective controlled trials with adequate follow-up, should be conducted in order to evaluate if the EVB prediction rate may be further improved by adding MDCT to currently validated modalities (*i.e.* liver disease scores combined with endoscopy and/or HVPG). Moreover, the capability of selected and standardizable MDCT parameters to predict EVB should be prospectively evaluated, adopting EGD with or without HVPG as the reference standards. MDCT should be performed at the same time as the other validated modalities, without significant delay, and results should be stratified according to liver disease scores, endoscopic scores, and cirrhotic etiology. Of note, no significant differences in terms of liver disease severity, etiology, ongoing liver injury, or prophylactic therapy should be encountered between the enrolled groups. High morbidity and mortality rates still associated with EVB justify active research in this field.

**ACKNOWLEDGEMENTS**

We are grateful to Velia De Magistris for English editing.

**REFERENCES**

1 **D'Amico G**, De Franchis R; Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. *Hepatology* 2003; **38**: 599-612 [PMID: 12939586 DOI: 10.1053/jhep.2003.50385]

2 **D'Amico G**, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. Clinical states of cirrhosis and competing risks. *J Hepatol* 2018; **68**: 563-576 [PMID: 29111320 DOI: 10.1016/j.jhep.2017.10.020]

3 **North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices**. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. *N Engl J Med* 1988; **319**: 983-989 [PMID: 3262200 DOI: 10.1056/NEJM198810133191505]

4 **Seo YS**. Prevention and management of gastroesophageal varices. *Clin Mol Hepatol* 2018; **24**: 20-42 [PMID: 29249128 DOI: 10.3350/cmh.2017.0064][](https://sci-hub.se/10.3350/cmh.2017.0064)

5 **Amitrano L**, Guardascione MA, Manguso F, Bennato R, Bove A, DeNucci C, Lombardi G, Martino R, Menchise A, Orsini L, Picascia S, Riccio E. The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors. *Am J Gastroenterol* 2012; **107**: 1872-1878 [PMID: 23007003 DOI: 10.1038/ajg.2012.313]

6 **Stokkeland K**, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. *Hepatology* 2006; **43**: 500-505 [PMID: 16496319 DOI: 10.1002/hep.21089]

7 **Graham DY**, Smith JL. The course of patients after variceal hemorrhage. *Gastroenterology* 1981; **80**: 800-809 [PMID: 6970703]

8 **Garcia-Tsao G**, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. *Hepatology* 2008; **47**: 1764-1772 [PMID: 18435460 DOI: 10.1002/hep.22273]

9 **de Franchis R**, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. *J Hepatol* 2022; **76**: 959-974 [PMID: 35120736 DOI: 10.1016/j.jhep.2021.12.022]

10 **de Franchis R**; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015; **63**: 743-752 [PMID: 26047908 DOI: 10.1016/j.jhep.2015.05.022]

11 **Garcia-Tsao G**, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology* 2017; **65**: 310-335 [PMID: 27786365 DOI: 10.1002/hep.28906]

12 **European Association for the Study of the Liver.** EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018; **69**: 406-460 [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024]

13 **Gralnek IM**, Camus Duboc M, Garcia-Pagan JC, Fuccio L, Karstensen JG, Hucl T, Jovanovic I, Awadie H, Hernandez-Gea V, Tantau M, Ebigbo A, Ibrahim M, Vlachogiannakos J, Burgmans MC, Rosasco R, Triantafyllou K. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2022; **54**: 1094-1120 [PMID: 36174643 DOI: 10.1055/a-1939-4887]

14 **de Mattos ÂZ**, Terra C, Farias AQ, Bittencourt PL; Alliance of Brazilian Centers for Cirrhosis Care–the ABC Group. Primary prophylaxis of variceal bleeding in patients with cirrhosis: A comparison of different strategies. *World J Gastrointest Endosc* 2021; **13**: 628-637 [PMID: 35070024 DOI: 10.4253/wjge.v13.i12.628]

15 **Rigo GP**, Merighi A, Chahin NJ, Mastronardi M, Codeluppi PL, Ferrari A, Armocida C, Zanasi G, Cristani A, Cioni G. A prospective study of the ability of three endoscopic classifications to predict hemorrhage from esophageal varices. *Gastrointest Endosc* 1992; **38**: 425-429 [PMID: 1511815 DOI: 10.1016/s0016-5107(92)70470-2]

16 **Merkel C**, Zoli M, Siringo S, van Buuren H, Magalotti D, Angeli P, Sacerdoti D, Bolondi L, Gatta A. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. *Am J Gastroenterol* 2000; **95**: 2915-2920 [PMID: 11051368 DOI: 10.1111/j.1572-0241.2000.03204.x]

17 **Kishimoto R**, Chen M, Ogawa H, Wakabayashi MN, Kogutt MS. Esophageal varices: evaluation with transabdominal US. *Radiology* 1998; **206**: 647-650 [PMID: 9494481 DOI: 10.1148/radiology.206.3.9494481]

18 **Perri RE**, Chiorean MV, Fidler JL, Fletcher JG, Talwalkar JA, Stadheim L, Shah ND, Kamath PS. A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. *Hepatology* 2008; **47**: 1587-1594 [PMID: 18393388 DOI: 10.1002/hep.22219]

19 **Yu NC**, Margolis D, Hsu M, Raman SS, Lu DS. Detection and grading of esophageal varices on liver CT: comparison of standard and thin-section multiplanar reconstructions in diagnostic accuracy. *AJR Am J Roentgenol* 2011; **197**: 643-649 [PMID: 21862806 DOI: 10.2214/AJR.10.5458]

20 **La Mura V**, Nicolini A, Tosetti G, Primignani M. Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. *World J Hepatol* 2015; **7**: 688-695 [PMID: 25866605 DOI: 10.4254/wjh.v7.i4.688]

21 **Bosch J**, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. *Nat Rev Gastroenterol Hepatol* 2009; **6**: 573-582 [PMID: 19724251 DOI: 10.1038/nrgastro.2009.149]

22 **Viallet A**, Marleau D, Huet M, Martin F, Farley A, Villeneuve JP, Lavoie P. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. *Gastroenterology* 1975; **69**: 1297-1300 [PMID: 1081459]

23 **Vinel JP**, Cassigneul J, Levade M, Voigt JJ, Pascal JP. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. *Hepatology* 1986; **6**: 116-117 [PMID: 3484713 DOI: 10.1002/hep.1840060122]

24 **D'Amico G**, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. *Gastroenterology* 2006; **131**: 1611-1624 [PMID: 17101332 DOI: 10.1053/j.gastro.2006.09.013]

25 **Hicken BL**, Sharara AI, Abrams GA, Eloubeidi M, Fallon MB, Arguedas MR. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. *Aliment Pharmacol Ther* 2003; **17**: 145-153 [PMID: 12492744 DOI: 10.1046/j.1365-2036.2003.01391.x]

26 **Thalheimer U**, Mela M, Patch D, Burroughs AK. Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence. *Gut* 2004; **53**: 143-148 [PMID: 14684589 DOI: 10.1136/gut.53.1.143]

27 **Tseng YJ**, Zeng XQ, Chen J, Li N, Xu PJ, Chen SY. Computed tomography in evaluating gastroesophageal varices in patients with portal hypertension: A meta-analysis. *Dig Liver Dis* 2016; **48**: 695-702 [PMID: 27103357 DOI: 10.1016/j.dld.2016.02.007]

28 **Somsouk M**, To'o K, Ali M, Vittinghoff E, Yeh BM, Yee J, Monto A, Inadomi JM, Aslam R. Esophageal varices on computed tomography and subsequent variceal hemorrhage. *Abdom Imaging* 2014; **39**: 251-256 [PMID: 24366107 DOI: 10.1007/s00261-013-0057-x]

29 **Ge W**, Wang Y, Cao YJ, Xie M, Ding YT, Zhang M, Yu DC. Radiological score for hemorrhage in the patients with portal hypertension. *Int J Clin Exp Pathol* 2015; **8**: 11517-11523 [PMID: 26617884]

30 **Calame P**, Ronot M, Bouveresse S, Cervoni JP, Vilgrain V, Delabrousse É. Predictive value of CT for first esophageal variceal bleeding in patients with cirrhosis: Value of para-umbilical vein patency. *Eur J Radiol* 2017; **87**: 45-52 [PMID: 28065374 DOI: 10.1016/j.ejrad.2016.12.006]

31 **Kim BH**, Chung JW, Lee CS, Jang ES, Jeong SH, Kim N, Kim JW. Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis. *Korean J Intern Med* 2019; **34**: 1233-1243 [PMID: 30759966 DOI: 10.3904/kjim.2018.120]

32 **Salahshour F**, Mehrabinejad MM, Rashidi Shahpasandi MH, Salahshour M, Shahsavari N, Nassiri Toosi M, Ayoobi Yazdi N. Esophageal variceal hemorrhage: the role of MDCT characteristics in predicting the presence of varices and bleeding risk. *Abdom Radiol (NY)* 2020; **45**: 2305-2314 [PMID: 32447415 DOI: 10.1007/s00261-020-02585-5]

33 **Xie W**, Chen FX, Zhu LY, Wen CC, Zhang X. Risk assessment of first upper gastrointestinal bleeding using computerized tomoscanning in esophageal varices patients with cirrhosis and portal hypertension. *Medicine (Baltimore)* 2020; **99**: e18923 [PMID: 32000404 DOI: 10.1097/MD.0000000000018923]

34 **Peisen F**, Ekert K, Bitzer M, Bösmüller H, Fritz J, Horger M. CT hepatic arterial perfusion index does not allow stratification of the degree of esophageal varices and bleeding risk in cirrhotic patients in Child-Pugh classes A and B. *Abdom Radiol (NY)* 2021; **46**: 5586-5597 [PMID: 34453180 DOI: 10.1007/s00261-021-03259-6]

35 **Wan S**, Wei Y, Zhang X, Yang C, Song B. CT-derived quantitative liver volumetric parameters for prediction of severe esophageal varices and the risk of first variceal hemorrhage. *Eur J Radiol* 2021; **144**: 109984 [PMID: 34638080 DOI: 10.1016/j.ejrad.2021.109984]

36 **Wan S**, He Y, Zhang X, Wei Y, Song B. Quantitative measurements of esophageal varices using computed tomography for prediction of severe varices and the risk of bleeding: a preliminary study. *Insights Imaging* 2022; **13**: 47 [PMID: 35286491 DOI: 10.1186/s13244-022-01189-5]

37 **Shimizu T**, Namba R, Matsuoka T, Tabuchi K, Yamamoto K, Uesugi Y, Matsui R, Sueyoshi K, Narabayashi I. Esophageal varices before and after endoscopic variceal ligation: evaluation using helical CT. *Eur Radiol* 1999; **9**: 1546-1549 [PMID: 10525862 DOI: 10.1007/s003300050881]

38 **Kim SH**, Kim YJ, Lee JM, Choi KD, Chung YJ, Han JK, Lee JY, Lee MW, Han CJ, Choi JI, Shin KS, Choi BI. Esophageal varices in patients with cirrhosis: multidetector CT esophagography--comparison with endoscopy. *Radiology* 2007; **242**: 759-768 [PMID: 17229872 DOI: 10.1148/radiol.2423050784]

39 **Kim YJ**, Raman SS, Yu NC, To'o KJ, Jutabha R, Lu DS. Esophageal varices in cirrhotic patients: evaluation with liver CT. *AJR Am J Roentgenol* 2007; **188**: 139-144 [PMID: 17179356 DOI: 10.2214/AJR.05.1737]

40 **Okuda K,** Matsutani S. Portal-systemic collaterals: anatomy and clinical implications. In: Okuda, K, Benhamou, editor. Portal Hypertension. Tokyo: Springer, 1991 [DOI:10.1007/978-4-431-68361-2\_5]

41 **Maruyama H**, Shiina S. Collaterals in portal hypertension: anatomy and clinical relevance. *Quant Imaging Med Surg* 2021; **11**: 3867-3881 [PMID: 34341755 DOI: 10.21037/qims-20-1328]

42 **Bandali MF**, Mirakhur A, Lee EW, Ferris MC, Sadler DJ, Gray RR, Wong JK. Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy. *World J Gastroenterol* 2017; **23**: 1735-1746 [PMID: 28348478 DOI: 10.3748/wjg.v23.i10.1735]

43 **Spiegel BM**, Targownik L, Dulai GS, Karsan HA, Gralnek IM. Endoscopic screening for esophageal varices in cirrhosis: Is it ever cost effective? *Hepatology* 2003; **37**: 366-377 [PMID: 12540787 DOI: 10.1053/jhep.2003.50050]

**Footnotes**

**Conflict-of-interest statement:** No conflict of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** Associazione Italiana Gastroenterologi ed endoscopisti digestivi Ospedalieri (AIGO); Società Italiana Di Gastroenterologia Ed Endoscopia Digestiva.

**Peer-review started:** September 27, 2023

**First decision:** November 1, 2023

**Article in press:** November 27, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chen CH, United States; Zhuge YZ, China **S-Editor:** Lin C **L-Editor:** A **P-Editor:** Cai YX

**Table 1 Characteristics of the included studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ref. | Study design | Country | Study type | Enrollment period |
| Somsouk *et al*[28], 2014 | R | United States | Unicentric | 2002-2007 |
| Ge *et al*[29], 2015 | R | China | Unicentric | 2008-2014 |
| Calame *et al*[30], 2017 | R | France | Unicentric | 2010-2012 |
| Kim *et al*[31], 2019 | R | South Korea | Unicentric | 2003-2015 |
| Salahshour *et al*[32], 2020 | R | Iran | Unicentric | 2013-2019 |
| Xie *et al*[33], 2020 | R | China | Unicentric | 2015-2018 |
| Peisen *et al*[34], 2021 | R | Germany | Unicentric | 2010-2019 |
| Wan *et al*[35], 2021 | R | China | Unicentric | 2014-2019 |
| Wan *et al*[36], 2022 | R | China | Unicentric | 2017-2020 |

**Table 2 Demographics and clinicopathological features of the included studies**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ref. | Patients, *n* | Mean age (range), years | Sex male, % | Cirrhosis etiology, % | Child-Pugh class, % | MELD score |
| Somsouk *et al*[28], 2014 | 80 (cases: 27; controls: 53) | Cases: 58 (-); Controls: 55 (-) | Cases: 96; Controls: 96 | HCV: 71 (cases); 77 (controls); HBV: 0 (cases); 9 (controls); Alcoholic: 83 (cases); 64 (controls) | - | -1 |
| Ge *et al*[29], 2015 | 98 (cases: 57; controls: 41) | Cases: 49.9 (-); Controls: 53.9 (-) | 56 | HBV: 100 | A: 15 (cases); 28 (controls); B: 21 (cases); 12 (controls); C: 5 (cases); 4 (controls) | - |
| Calame *et al*[30], 2017 | 172 (cases: 43; controls: 129) | Cases: 59.6 (12-85); Controls: 60.2 (33-86) | Cases: 77; Controls: 62 | Alcoholic: 77 (cases); 70 (controls); NASH: 9 (cases); 13(controls)  HCV: 9 (cases); 9 (controls); HBV: 7 (cases); 4 (controls); Other: 5 (cases); 13 (controls) | A: 16 (cases); 43 (controls); B: 46 (cases); 27 (controls); C: 37 (cases); 29 (controls) | - |
| Kim *et al*[31], 2019 | 309 (cases: 37; controls: 272) | Cases: 58 (-); Controls: 58 (-) | Cases: 81; Controls: 72 | HBV: 46 (cases); 61 (controls); HCV: 16 (cases); 7 (controls); Non-B/C: 38 (cases); 32 (controls) | A: 57 (cases); 48 (controls); B: 40 (cases); 44 (controls); C: 3 (cases); 8 (controls) | - |
| Salahshour *et al*[32], 2020 | 124 (cases: 50; controls: 74) | Cases: 49.2 (-); Controls: 52.14 (-) | Cases: 46; Controls: 54 | HBV: 24.2; HCV: 5.6; BCS: 8.1; Alcoholic: 9.7; NASH: 14.5; ASH: 4.0; PSC: 9.7; Wilson disease: 2.4; PBC: 1.6; Cryptogenic: 10.5; Other: 9.7 | -2 | -2 |
| Xie *et al*[33], 2020 | 264 (cases: 132; controls: 132) | Cases: 54 (30-76); Controls: 54 (25-79) | Cases: 85%; Controls: 88% | HBV: 87 (cases); 95 (controls); Alcoholic: 11 (cases); 1 (controls); HCV: 2 (cases); 4 (controls) | - | - |
| Peisen *et al*[34], 2021 | 66 (cases: 8; controls: 58) | 68 | 89 | HCV: 32; Alcoholic: 48; Cryptogenic: 14; HBV: 6 | A: 53%; B: 38%; C: 9% | - |
| Wan *et al*[35], 2021 | 217 (cases: 17; controls: 27) | Cases: 52.8; Controls: 52.4 | Cases: 53; Controls: 56 | Post-hepatic: 53 (cases); 41 (controls); Alcoholic: 18 (cases); 15 (controls); PBC: 29 (cases); 19 (controls); Mixed: 0 (cases); 7 (controls)  Other: 0 (cases); 19 (controls) | A: 47 (cases); 33 (controls); B: 35 (cases); 33 (controls); C: 18 (cases); 33 (controls) | - |
| Wan *et al*[36], 2022 | 136 (cases: 89; controls: 47) | - | 63 | Post-hepatic: 60; Alcoholic: 25; PBC: 9; Mixed: 4; AIH: 1 | A: 28; B: 46; C: 26 | - |

1No significant difference between case and control groups.

2Significant difference between case and control groups.

MELD: Model for end-stage liver disease; HCV: Hepatitis C virus; HBV: Hepatitis B virus; NASH: Nonalcoholic steatohepatitis; BCS: Budd-Chiari syndrome; AIH: Autoimmune hepatitis; PSC: Primary sclerosing cholangitis; PBC: Primary biliary cirrhosis.

**Table 3** **Summary of the included studies reporting on the role of computed tomography in the prediction of esophageal variceal bleeding**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ref. | Inclusion criteria | Exclusion criteria | Study aim | Results |
| Somsouk *et al*[28], 2014 | Cirrhotic patients with EVB who underwent CT prior to EVB (case group); cirrhotic patients without EVB who underwent CT and EGD within 45 d (control group) | Previous EVB, EVL, or OLT | To identify CT features associated with EVB | Features associated with EVB: EV diameter: 5.8 mm case group *vs.* 2.7 mm control group (*P* < 0.001); Maximal EV diameter ≥ 5 mm: 63% case group *vs.* 7.5% control group (*P* < 0.001); Maximal EV diameter < 3 mm: 7.4% case group *vs.* 54.7% control group (*P* = 0.001); LGV diameter: 2.3 mm case group *vs.* 1.6 mm control group (*P* = 0.001); PUV diameter: 1.9 mm case group *vs.* 1.1 mm control group (*P* < 0.001); Ascites: 74% case group *vs.* 25% control group (*P* < 0.001) |
| Ge *et al*[29], 2015 | HBV-related cirrhotic patients who underwent CT | HCC, PVT, and non HBV-related cirrhosis | To identify CT features associated with EVB | Features associated with EVB: IMV diameter (*P* = 0.0528); PGV diameter (*P* = 0.0283); EV score (*P* = 0.0221) |
| Calame *et al*[30], 2017 | Cirrhotic patients who underwent CT and EGD within 6 mo | BB, TIPS, EVL, PVT, liver resection/loco-regional treatment, and esophageal cancer | To evaluate the association between the presence/size of PUV on CT and first EVB | Features associated with first EVB: Small/absent PUV (*P* < 0.001); Spleen size >135 mm (*P* < 0.001); Ascites (*P* = 0.001) |
| Kim *et al*[31], 2019 | Cirrhotic patients receiving propranolol for the primary prophylaxis of EVB who underwent CT | Duration of propranolol prophylaxis < 6 mo, previous EVB and/or EVL before propranolol therapy, and lack of contrast-enhanced liver CT data within 6 mo before or after first propranolol dosage | To evaluate liver volume for the prediction of EVB during primary prophylaxis | Association of liver volume index with EVB (*P* = 0.044) |
| Salahshour *et al*[32], 2020 | Cirrhotic patients who underwent EGD and CT within 6 mo | Liver resection/loco-regional treatment, and esophageal cancer | To identify CT features associated with EVB | Features associated with EVB: EV presence (*P* = 0.002); Short gastric collateral presence/size (*P* < 0.001/*P* < 0.001); Coronary collateral presence (*P* = 0.02); Paraesophageal collateral presence/size (*P* = 0.01/*P* = 0.03); Paraesophageal draining collateral presence/size (*P* = 0.02/*P* = 0.02); LGV size (*P* = 0.03); Gastric fundus varices size (*P* = 0.001); IMV size (*P* = 0.04); Ascites (*P* = 0.04) |
| Xie *et al*[33], 2020 | Cirrhotic patients with EV who underwent EGD and CT, and were followed-up for 6 mo | Cardiovascular disease, hematologic disease, renal insufficiency, or malignancy; previous shunt, devascularization,EIS, or EVL; use of vasopressin, somatostatin or propranolol within 1 wk before hospitalization;  NVUGIB | To evaluate sensitivity and specificity of EV diameter, EV cross-sectional number, and EV total area in the prediction of first EVB | EV diameter: Sensitivity 0.8; specificity 0.52; AUC 0.72; critical point 5.55 mm; EV cross-sectional number: sensitivity 0.73; specificity 0.6; AUC 0.68; critical point 4; EV total cross-sectional area: sensitivity 0.75; specificity 0.73; AUC 0.82; critical point 1.03 cm2 |
| Peisen *et al*[34], 2021 | Cirrhotic patients who underwent PCT and EGD within 3 mo | Diffusely infiltrating  HCC, TIPS, and PVT | To evaluate the correlation between PCT-derived variables (HPI, PVP and SBF) and EVB | Weak correlation of HPI, PVP, and SBF with EBV (Eta correlation coefficient 0.126, 0.031, and 0.119, respectively) |
| Wan *et al*[35], 2021 | Cirrhotic patients with EV who underwent EGD and CT within 4 wk | Prior EV treatment (*e.g.* BB, EVL); PVT;  HCC; splenectomy, hepatectomy or portal-azygous disconnection | To identify CT-derived quantitative parameters of liver lobe associated with first EVB | Features associated with first EVB: CV (*P* = 0.012); CFV (*P* = 0.03); CV/TV (*P* < 0.001); CFV/TFV (*P* < 0.001) |
| Wan *et al*[36], 2022 | Cirrhotic patients with EV who underwent contrast-enhanced CT within 4 wk of EGD | Prior EV treatment (*e.g.*, BB, EVL); PVT; HCC; splenectomy, hepatectomy or portal-azygous disconnection | To identify CT quantitative parameters associated with EVB | No significant difference in EV grade, EV diameter, CSA, EV volume, SNV, LGV diameter, PV, SV, and the opening type of LGV between bleeding and non-bleeding groups |

EVB: Esophageal variceal bleeding; CT: Computed tomography; EGD: Esophagogastroduodenoscopy; EVL: Endoscopic variceal ligation; OLT: Orthotopic liver transplantation; EV: Esophageal varices; PUV: Paraumbilical vein; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; PVT: Portal vein thrombosis; IMV: Inferior mesenteric vein; PGV: Posterior gastric vein; BB: Beta-blockers; TIPS: Transjugular intrahepatic portosystemic shunt; EIS: Endoscopic injection sclerotherapy; NVUGIB: Nonvariceal upper gastrointestinal bleeding; AUC: Area under the curve; PCT: Perfusion computed tomography; HPI: Hepatic perfusion index; PVP: Portal venous perfusion; SBF: Splenic blood flow; CV: Caudate lobe volume; CFV: Caudate lobe functional volume; TV: Total volume; TFV: Total functional volume; CSA: Cross-sectional surface area; SNV: Splenic vein; LGV: Left gastric vein; PV: Portal vein; SV: Spleen volume.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**